EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, and internationally. It offers DiaSpect Tm, an hemoglobin analyzer; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a centrifuge that provides a hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+, C-Line Clinic, and S-Line Lab+; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer for use in the determination of BHB in serum or plasma in ketosis patients. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; True20 and QuPID pregnancy tests for testing urine only or urine and serum; SensPoint, a lactate analyzer with docking station; and Lactate Scout+, a lactate analyzer. Further, the company offers Altair 240, an analyzer calibrated to run the Stanbio chemistry range of reagents; reagents, such as BHB for detecting ketosis, Procalcitonin for detecting sepsis, and glycated serum protein for use in the diagnosis and screening of diabetes; and contract manufacturing services, as well as services and distributes third party company products. It sells its products directly to GP surgeries, sports and diabetes clinics, blood banks, hospitals, laboratories, and government agencies, as well as through a network of distributors. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.
